まとめ
慢性小脳刺激 (C.C.S.) とは 脳性麻痺の改善と発作の軽減に有望であることが示されています. この神経刺激技術は,脳幹の構造を阻害することで作用し,安全な治療の選択肢を提供します.
科学分野:
- 神経科学は神経科学である.
- 神経学 神経学とは
- バイオメディカルエンジニアリング
背景:
- 慢性小脳刺激 (C.C.S.) とは 神経学的障害に対する調査中の技術です.
- 以前の研究では,潜在的な利点が示唆されているが,その背後にあるメカニズムについては,さらなる解明が必要である.
研究 の 目的:
- c.c.s.s.に関する臨床および神経生理学的データをレビューする. 脳性麻痺と治療不可能な発作の患者に投与する.
- 脳幹構造とタラミック阻害に対する効果を含む,c.c.s.の潜在的な作用メカニズムを探求する.
主な方法:
- 200人の患者の臨床結果のレビュー.
- 42人の患者の神経生理学的結果を分析した.
- 誘発電位とパラキシズマルの放電を含む脳波 (EEG) データの検査.
主要な成果:
- c.c.s.c.s.は,C.C.S.C.S.と,C.C.S.S.は,C.C.S.S.と,C.C.S.S.は,C.C.S.S.と,C.C.S.S.は,C.C.S.S.と,C.C.S.S.は,C.S.S.は,C.S.S.は,C.S.S.は,C.S.S.は,C.S.S.は,C.S.S.は,C.S.S.は,C.S.S.は,C.S.は,C.S.S.は,C.S.は,C.S.S.は,C.S.は,C.S.S.は,C.S.は,C.S.S.は,C.S.は,C.S.S.は,C.S.S.は,C.S.S.は,C.S.S.は,C.S.と,C.S.S.S.は,C.S.S.とされている 脳性麻痺の改善と治療不可能な発作の減少が実証されました.
- 治療効果は,直接的なプルキンジェ細胞活性化ではなく,脳幹刺激と,その後のタラミック阻害から生じる可能性があります.
- 観察された効果には,長時間,リバウンド,パラドックス,および累積的な反応が含まれます.
- c.c.s.s.の5年間にわたり,有意な臨床的障害や組織損傷は報告されなかった. 使用する. 使用する.
結論:
- c.c.s.c.s.は,C.C.S.C.S.と,C.C.S.S.は,C.C.S.S.と,C.C.S.S.は,C.C.S.S.と,C.C.S.S.は,C.C.S.S.と,C.C.S.S.は,C.S.S.は,C.S.S.は,C.S.S.は,C.S.S.は,C.S.S.は,C.S.S.は,C.S.S.は,C.S.S.は,C.S.は,C.S.S.は,C.S.は,C.S.S.は,C.S.は,C.S.S.は,C.S.は,C.S.S.は,C.S.は,C.S.S.は,C.S.S.は,C.S.S.は,C.S.S.は,C.S.と,C.S.S.S.は,C.S.S.とされている 特定の神経学的状態に対する潜在的に有効で安全な治療的介入である.
- このメカニズムは,中枢神経系内の抑制・消毒経路の調節を伴う可能性が高い.
- 脳幹とthalamicの相互作用に関するさらなる研究は,c.c.s.s.を完全に理解するために正当化されています. 効能. 効能. 効能. 効能. 効能. 効能. 効能. 効能. 効能. 効能.
関連する概念動画
Long-term Potentiation
Long-term potentiation, or LTP, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTP is the process of synaptic strengthening that occurs over time between pre- and postsynaptic neuronal connections. The synaptic strengthening of LTP works in opposition to the synaptic weakening of long-term depression (LTD) and together are the main mechanisms that underlie learning and memory.
Long-term Depression
Long-term depression, or LTD, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTD is the process of synaptic weakening that occurs over time between pre and postsynaptic neuronal connections. The synaptic weakening of LTD works in opposition to synaptic strengthening by long-term potentiation (LTP) and together are the main mechanisms that underlie learning and memory.
Long-term Depression
Long-term depression, or LTD, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTD is the process of synaptic weakening that occurs over time between pre and postsynaptic neuronal connections. The synaptic weakening of LTD works in opposition to synaptic strengthening by long-term potentiation (LTP) and together are the main mechanisms that underlie learning and memory.
Calcium Ion Concentration Mechanism
If over time, all...
Calcium Ion Concentration Mechanism
If over time, all...
Desensitization and Tachyphylaxis
Tachyphylaxis is described as a rapid decrease in response to a drug after repeated or continuous administration of the same drug dose. It is a phenomenon where the body becomes less responsive to a particular substance or intervention over time, requiring higher doses or stronger interventions to achieve the same effect. It results from adaptive changes in the body's receptors, signaling pathways, or physiological processes that occur in response to prolonged exposure to a stimulus.
Several...
Several...
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function. They...
Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...


